Evidence map›Paper›PMID 35147767›Full record

Trial reportClinical research in cardiology : official journal of the German Cardiac Society2022

Target and non-target vessel related events at 10 years post percutaneous coronary intervention.

J J Coughlan, Alp Aytekin, Erion Xhepa, Salvatore Cassese, Michael Joner, Tobias Koch, Jens Wiebe, Tobias Lenz, Tobias Rheude, Constanza Pellegrini and 6 more

2 registry-linked trialsOpen access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Clinical research in cardiology : official journal of the German Cardiac Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00598533 phase4completednot on this map

Prospective, Randomized Trial of Rapamycin- and Zotarolimus-eluting Stents for the Reduction of Coronary Restenosis

TypeinterventionalSponsorDeutsches Herzzentrum MuenchenRan2008 to 2010Enrolled3,002ConditionsCoronary Heart DiseaseArmsRapamycin + Probucol-eluting stent (ISAR stent), polymer based Zotarolimus-eluting stent (Endeavor Resolute)
NCT00598676 phase4completednot on this map

Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting STents (ISAR-TEST 4): Prospective, Randomized Trial of 3-limus Agent-eluting Stents With Different Polymer Coatings

TypeinterventionalSponsorDeutsches Herzzentrum MuenchenRan2007 to 2009Enrolled2,600ConditionsCoronary Heart DiseaseArmsbiodegradable polymer Rapamycin-eluting stent, permanent polymer rapamycin-eluting stent (Cypher), permanent polymer everolimus-eluting stent (Xience, Promus)
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Incidence and pattern of urgent revascularization in acute coronary syndromes treated with ticagrelor or prasugrel.Clinical research in cardiology : official journal of the German Cardiac Society · 2024
    Trial
  2. Comparison of the Effects of Indobufen and Aspirin in Older Patients with Coronary Artery Disease After Coronary Drug-Eluting Stent Implantation: A Prospective Randomized Single-Center Study.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

J J CoughlanDeutsches Herzzentrum München, Technische Universität München, Lazarettstrasse, 36, Munich, Germany.ORCID http://orcid.org/0000-0001-6086-3279
Alp AytekinDeutsches Herzzentrum München, Technische Universität München, Lazarettstrasse, 36, Munich, Germany.
Erion XhepaDeutsches Herzzentrum München, Technische Universität München, Lazarettstrasse, 36, Munich, Germany.
Salvatore CasseseDeutsches Herzzentrum München, Technische Universität München, Lazarettstrasse, 36, Munich, Germany.
Michael JonerDeutsches Herzzentrum München, Technische Universität München, Lazarettstrasse, 36, Munich, Germany.
Tobias KochDeutsches Herzzentrum München, Technische Universität München, Lazarettstrasse, 36, Munich, Germany.
Jens WiebeDeutsches Herzzentrum München, Technische Universität München, Lazarettstrasse, 36, Munich, Germany.
Tobias LenzDeutsches Herzzentrum München, Technische Universität München, Lazarettstrasse, 36, Munich, Germany.
Tobias RheudeDeutsches Herzzentrum München, Technische Universität München, Lazarettstrasse, 36, Munich, Germany.
Constanza PellegriniDeutsches Herzzentrum München, Technische Universität München, Lazarettstrasse, 36, Munich, Germany.
Senta GewaltDeutsches Herzzentrum München, Technische Universität München, Lazarettstrasse, 36, Munich, Germany.
Tareq IbrahimKlinik Und Poliklinik Innere Medizin I (Kardiologie, Angiologie Und Pneumologie), Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Karl-Ludwig LaugwitzKlinik Und Poliklinik Innere Medizin I (Kardiologie, Angiologie Und Pneumologie), Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Heribert SchunkertDeutsches Herzzentrum München, Technische Universität München, Lazarettstrasse, 36, Munich, Germany.
Adnan KastratiDeutsches Herzzentrum München, Technische Universität München, Lazarettstrasse, 36, Munich, Germany.
Sebastian KufnerDeutsches Herzzentrum München, Technische Universität München, Lazarettstrasse, 36, Munich, Germany. Sebastian.Kufner@gmx.de.
Deutsches Herzzentrum München · DETUM Klinikum · DEGerman Centre for Cardiovascular Research · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo define the incidence of events related to the stented vessel (target vessel related events: TVRE) and events related to non-stented vessels (non-target vessel related events: NTVRE) through to 10-year follow-up in patients post-PCI with newer generation drug eluting stents (DES). METHODS AND

resultsThe current study is a post-hoc analysis of patient level data from two randomised controlled trials in Germany. Patients older than 18 years with ischemic symptoms or evidence of myocardial ischemia in the presence of ≥ 50% de novo stenosis located in the native coronary vessels were considered eligible. The endpoints of interest were TVRE (a composite of first target vessel myocardial infarction or target vessel revascularization) and NTVRE (a composite of first non-target vessel MI or non-target vessel revascularization) through to 10 years post PCI. We included 4953 patients in this analysis. Through to 10-years post-PCI, TVRE occurred in 1238 of 4953 patients (cumulative incidence: 25.8%) and NTVRE occurred in 1442 of 4953 patients (cumulative incidence: 30.3%). The majority of TVRE and NTVRE were revascularization events. From 0 to 1 years, the cumulative incidence of TVRE was 15.9% and of NTVRE was 12.3%. From 1 to 10 years, the cumulative incidences of TVRE and NTVRE were 11.2% and 22.4%, respectively.

conclusionAt 10-year post-PCI with new generation drug eluting stents, events related to remote vessel disease progression account for a higher proportion of events than events related to the stented vessel.

trial registrationISAR TEST 4 ClinicalTrials.gov Identifier: NCT00598676. ISAR TEST 5 ClinicalTrials.gov Identifier: NCT00598533.

Indexed as

Coronary Artery DiseaseDrug-Eluting StentsMyocardial InfarctionPercutaneous Coronary InterventionHumansRisk FactorsTreatment OutcomeAtherosclerotic coronary artery diseaseCardiovascular outcomesDrug eluting stentsPercutaneous coronary interventionTarget vessel

Identifiers

PMID35147767
PMCPMC9242894
OpenAlexW4210952766

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.